A Phase II HIV Antiviral from France Has Promising Results

Abivax in Paris (France) has released its phase IIa clinical results for an antiviral therapy for patients with HIV infection, which could potentially take a corner in an annual $18Bn market.

HIV and AIDs have a long-standing history (the quick – yet fascinating story of which can be read here), and since 1983 (when the HIV virus was identified to be responsible for this mystery disease) the WHO estimates 25 million to have died from its grasp.

To view article, click here

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here